2
|
Bartzsch S, Corde S, Crosbie JC, Day L, Donzelli M, Krisch M, Lerch M, Pellicioli P, Smyth LML, Tehei M. Technical advances in x-ray microbeam radiation therapy. Phys Med Biol 2020; 65:02TR01. [PMID: 31694009 DOI: 10.1088/1361-6560/ab5507] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
In the last 25 years microbeam radiation therapy (MRT) has emerged as a promising alternative to conventional radiation therapy at large, third generation synchrotrons. In MRT, a multi-slit collimator modulates a kilovoltage x-ray beam on a micrometer scale, creating peak dose areas with unconventionally high doses of several hundred Grays separated by low dose valley regions, where the dose remains well below the tissue tolerance level. Pre-clinical evidence demonstrates that such beam geometries lead to substantially reduced damage to normal tissue at equal tumour control rates and hence drastically increase the therapeutic window. Although the mechanisms behind MRT are still to be elucidated, previous studies indicate that immune response, tumour microenvironment, and the microvasculature may play a crucial role. Beyond tumour therapy, MRT has also been suggested as a microsurgical tool in neurological disorders and as a primer for drug delivery. The physical properties of MRT demand innovative medical physics and engineering solutions for safe treatment delivery. This article reviews technical developments in MRT and discusses existing solutions for dosimetric validation, reliable treatment planning and safety. Instrumentation at synchrotron facilities, including beam production, collimators and patient positioning systems, is also discussed. Specific solutions reviewed in this article include: dosimetry techniques that can cope with high spatial resolution, low photon energies and extremely high dose rates of up to 15 000 Gy s-1, dose calculation algorithms-apart from pure Monte Carlo Simulations-to overcome the challenge of small voxel sizes and a wide dynamic dose-range, and the use of dose-enhancing nanoparticles to combat the limited penetrability of a kilovoltage energy spectrum. Finally, concepts for alternative compact microbeam sources are presented, such as inverse Compton scattering set-ups and carbon nanotube x-ray tubes, that may facilitate the transfer of MRT into a hospital-based clinical environment. Intensive research in recent years has resulted in practical solutions to most of the technical challenges in MRT. Treatment planning, dosimetry and patient safety systems at synchrotrons have matured to a point that first veterinary and clinical studies in MRT are within reach. Should these studies confirm the promising results of pre-clinical studies, the authors are confident that MRT will become an effective new radiotherapy option for certain patients.
Collapse
Affiliation(s)
- Stefan Bartzsch
- Department of Radiation Oncology, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany. Helmholtz Centre Munich, Institute for Radiation Medicine, Munich, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Dilmanian FA, Krishnan S, McLaughlin WE, Lukaniec B, Baker JT, Ailawadi S, Hirsch KN, Cattell RF, Roy R, Helfer J, Kruger K, Spuhler K, He Y, Tailor R, Vassantachart A, Heaney DC, Zanzonico P, Gobbert MK, Graf JS, Nassimi JR, Fatemi NN, Schweitzer ME, Bangiyev L, Eley JG. Merging Orthovoltage X-Ray Minibeams spare the proximal tissues while producing a solid beam at the target. Sci Rep 2019; 9:1198. [PMID: 30718607 PMCID: PMC6362296 DOI: 10.1038/s41598-018-37733-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2017] [Accepted: 12/07/2018] [Indexed: 02/07/2023] Open
Abstract
Conventional radiation therapy of brain tumors often produces cognitive deficits, particularly in children. We investigated the potential efficacy of merging Orthovoltage X-ray Minibeams (OXM). It segments the beam into an array of parallel, thin (~0.3 mm), planar beams, called minibeams, which are known from synchrotron x-ray experiments to spare tissues. Furthermore, the slight divergence of the OXM array make the individual minibeams gradually broaden, thus merging with their neighbors at a given tissue depth to produce a solid beam. In this way the proximal tissues, including the cerebral cortex, can be spared. Here we present experimental results with radiochromic films to characterize the method's dosimetry. Furthermore, we present our Monte Carlo simulation results for physical absorbed dose, and a first-order biologic model to predict tissue tolerance. In particular, a 220-kVp orthovoltage beam provides a 5-fold sharper lateral penumbra than a 6-MV x-ray beam. The method can be implemented in arc-scan, which may include volumetric-modulated arc therapy (VMAT). Finally, OXM's low beam energy makes it ideal for tumor-dose enhancement with contrast agents such as iodine or gold nanoparticles, and its low cost, portability, and small room-shielding requirements make it ideal for use in the low-and-middle-income countries.
Collapse
Affiliation(s)
- F Avraham Dilmanian
- Department of Radiology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA.
- Department of Radiation Oncology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA.
- Department of Neurology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA.
- Department of Psychiatry, Stony Brook University Hospital, Stony Brook, NY, 11794, USA.
- Department of Biomedical Engineering, Stony Brook University Hospital, Stony Brook, NY, 11794, USA.
- Stony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY, 11794, USA.
| | - Sunil Krishnan
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
| | | | | | - Jameson T Baker
- Department of Radiation Oncology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
- Department of Radiation Medicine, Northwell Health Medical Center, Northwell, NY, USA
| | - Sandeep Ailawadi
- Department of Radiation Oncology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
| | - Kara N Hirsch
- Department of Radiology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
| | - Renee F Cattell
- Department of Radiology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
- Department of Biomedical Engineering, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
| | - Rahul Roy
- Department of Radiation Oncology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
| | - Joel Helfer
- Precision X-ray Inc., North Branford, CT, 06471, USA
| | - Kurt Kruger
- Precision X-ray Inc., North Branford, CT, 06471, USA
| | - Karl Spuhler
- Department of Radiology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
| | - Yulun He
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - Ramesh Tailor
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | | | - Dakota C Heaney
- Department of Radiology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
- Department of Radiation Oncology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
| | - Pat Zanzonico
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Matthias K Gobbert
- Department of Mathematics and Statistics, University of Maryland, Baltimore County, Baltimore, MD, 21250, USA
| | - Jonathan S Graf
- Department of Mathematics and Statistics, University of Maryland, Baltimore County, Baltimore, MD, 21250, USA
| | - Jessica R Nassimi
- Department of Radiology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
| | - Nasrin N Fatemi
- Department of Radiology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
- Department of Radiology, City of Hope, Duarte, CA, 91010, USA
| | - Mark E Schweitzer
- Department of Radiology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
| | - Lev Bangiyev
- Department of Radiology, Stony Brook University Hospital, Stony Brook, NY, 11794, USA
| | - John G Eley
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA
| |
Collapse
|
4
|
Dilmanian FA, Eley JG, Rusek A, Krishnan S. Charged Particle Therapy with Mini-Segmented Beams. Front Oncol 2015; 5:269. [PMID: 26649281 PMCID: PMC4664668 DOI: 10.3389/fonc.2015.00269] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Accepted: 11/16/2015] [Indexed: 02/06/2023] Open
Abstract
One of the fundamental attributes of proton therapy and carbon ion therapy is the ability of these charged particles to spare tissue distal to the targeted tumor. This significantly reduces normal tissue toxicity and has the potential to translate to a wider therapeutic index. Although, in general, particle therapy also reduces dose to the proximal tissues, particularly in the vicinity of the target, dose to the skin and to other very superficial tissues tends to be higher than that of megavoltage x-rays. The methods presented here, namely, “interleaved carbon minibeams” and “radiosurgery with arrays of proton and light ion minibeams,” both utilize beams segmented into arrays of parallel “minibeams” of about 0.3 mm incident-beam size. These minibeam arrays spare tissues, as demonstrated by synchrotron x-ray experiments. An additional feature of particle minibeams is their gradual broadening due to multiple Coulomb scattering as they penetrate tissues. In the case of interleaved carbon minibeams, which do not broaden much, two arrays of planar carbon minibeams that remain parallel at target depth, are aimed at the target from 90° angles and made to “interleave” at the target to produce a solid radiation field within the target. As a result, the surrounding tissues are exposed only to individual carbon minibeam arrays and are therefore spared. The method was used in four-directional geometry at the NASA Space Radiation Laboratory to ablate a 6.5-mm target in a rabbit brain at a single exposure with 40 Gy physical absorbed dose. Contrast-enhanced magnetic resonance imaging and histology 6-month later showed very focal target necrosis with nearly no damage to the surrounding brain. As for minibeams of protons and light ions, for which the minibeam broadening is substantial, measurements at MD Anderson Cancer Center in Houston, TX, USA; and Monte Carlo simulations showed that the broadening minibeams will merge with their neighbors at a certain tissue depth to produce a solid beam to treat the target. The resulting sparing of proximal normal tissue allows radiosurgical ablative treatments with smaller impact on the skin and shallow tissues. This report describes these two methods and discusses their potential clinical applications.
Collapse
Affiliation(s)
- F Avraham Dilmanian
- Department of Radiation Oncology, Health Sciences Center, Stony Brook University , Stony Brook, NY , USA ; Department of Neurology, Health Sciences Center, Stony Brook University , Stony Brook, NY , USA ; Department of Radiology, Health Sciences Center, Stony Brook University , Stony Brook, NY , USA
| | - John G Eley
- Department of Radiation Oncology, School of Medicine, University of Maryland , Baltimore, MD , USA
| | - Adam Rusek
- Brookhaven National Laboratory , Upton, NY , USA ; NASA Space Radiation Laboratory , Upton, NY , USA
| | - Sunil Krishnan
- Department of Radiation Oncology, MD Anderson Cancer Center , Houston, TX , USA
| |
Collapse
|
5
|
Dilmanian FA, Eley JG, Krishnan S. Minibeam therapy with protons and light ions: physical feasibility and potential to reduce radiation side effects and to facilitate hypofractionation. Int J Radiat Oncol Biol Phys 2015; 92:469-74. [PMID: 25771360 DOI: 10.1016/j.ijrobp.2015.01.018] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Revised: 12/02/2014] [Accepted: 01/13/2015] [Indexed: 11/18/2022]
Abstract
PURPOSE Despite several advantages of proton therapy over megavoltage x-ray therapy, its lack of proximal tissue sparing is a concern. The method presented here adds proximal tissue sparing to protons and light ions by turning their uniform incident beams into arrays of parallel, small, or thin (0.3-mm) pencil or planar minibeams, which are known to spare tissues. As these minibeams penetrate the tissues, they gradually broaden and merge with each other to produce a solid beam. METHODS AND MATERIALS Broadening of 0.3-mm-diameter, 109-MeV proton pencil minibeams was measured using a stack of radiochromic films with plastic spacers. Monte Carlo simulations were used to evaluate the broadening in water of minibeams of protons and several light ions and the dose from neutron generated by collimator. RESULTS A central parameter was tissue depth, where the beam full width at half maximum (FWHM) reached 0.7 mm, beyond which tissue sparing decreases. This depth was 22 mm for 109-MeV protons in a film stack. It was also found by simulations in water to be 23.5 mm for 109 MeV proton pencil minibeams and 26 mm for 116 MeV proton planar minibeams. For light ions, all with 10 cm range in water, that depth increased with particle size; specifically it was 51 mm for Li-7 ions. The ∼2.7% photon equivalent neutron skin dose from the collimator was reduced 7-fold by introducing a gap between the collimator and the skin. CONCLUSIONS Proton minibeams can be implemented at existing particle therapy centers. Because they spare the shallow tissues, they could augment the efficacy of proton therapy and light particle therapy, particularly in treating tumors that benefit from sparing of proximal tissues such as pediatric brain tumors. They should also allow hypofractionated treatment of all tumors by allowing the use of higher incident doses with less concern about proximal tissue damage.
Collapse
Affiliation(s)
- F Avraham Dilmanian
- Departments of Radiation Oncology, Neurology, and Radiology, Stony Brook University Medical Center, Stony Brook, New York.
| | - John G Eley
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Sunil Krishnan
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
6
|
Yang Y, Crosbie JC, Paiva P, Ibahim M, Stevenson A, Rogers PAW. In vitro study of genes and molecular pathways differentially regulated by synchrotron microbeam radiotherapy. Radiat Res 2015; 182:626-39. [PMID: 25409126 DOI: 10.1667/rr13778.1] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The aim of this study was to identify genes and molecular pathways differentially regulated by synchrotron-generated microbeam radiotherapy (MRT) versus conventional broadbeam radiotherapy (CRT) in vitro using cultured EMT6.5 cells. We hypothesized (based on previous findings) that gene expression and molecular pathway changes after MRT are different from those seen after CRT. We found that at 24 h postirradiation, MRT exerts a broader regulatory effect on multiple pathways than CRT. MRT regulated those pathways involved in gene transcription, translation initiation, macromolecule metabolism, oxidoreductase activity and signaling transduction in a different manner compared to CRT. We also found that MRT/CRT alone, or when combined with inflammatory factor lipopolysaccharide, upregulated expression of Ccl2, Ccl5 or Csf2, which are involved in host immune cell recruitment. Our findings demonstrated differences in the molecular pathway for MRT versus CRT in the cultured tumor cells, and were consistent with the idea that radiation plays a role in recruiting tumor-associated immune cells to the tumor. Our results also suggest that a combination of MRT/CRT with a treatment targeting CCL2 or CSF2 could repress the tumor-associated immune cell recruitment, delay tumor growth and/or metastasis and yield better tumor control than radiation alone.
Collapse
Affiliation(s)
- Yuqing Yang
- a Department of Obstetrics and Gynaecology, The University of Melbourne, Royal Women's Hospital, Parkville, Victoria 3052, Australia
| | | | | | | | | | | |
Collapse
|
7
|
Fontanella AN, Boss MK, Hadsell M, Zhang J, Schroeder T, Berman KG, Dewhirst MW, Chang S, Palmer GM. Effects of high-dose microbeam irradiation on tumor microvascular function and angiogenesis. Radiat Res 2015; 183:147-58. [PMID: 25574586 DOI: 10.1667/rr13712.1] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Microbeam radiation therapy (MRT) is a form of cancer treatment in which a single large dose of radiation is spatially fractionated in-line or grid-like patterns. Preclinical studies have demonstrated that MRT is capable of eliciting high levels of tumor response while sparing normal tissue that is exposed to the same radiation field. Since a large fraction of the MRT-treated tumor is in the dose valley region that is not directly irradiated, tumor response may be driven by radiation bystander effects, which in turn elicit a microvascular response. Differential alterations in hemodynamics between the tumor and normal tissue may explain the therapeutic advantages of MRT. Direct observation of these dynamic responses presents a challenge for conventional ex vivo analysis. Furthermore, knowledge gleaned from in vitro studies of radiation bystander response has not been widely incorporated into in vivo models of tumor radiotherapy, and the biological contribution of the bystander effect within the tumor microenvironment is unknown. In this study, we employed noninvasive, serial observations of the tumor microenvironment to address the question of how tumor vasculature and HIF-1 expression are affected by microbeam radiotherapy. Tumors (approximately 4 mm in diameter) grown in a dorsal window chamber were irradiated in a single fraction using either a single, microplanar beam (300 micron wide swath) or a wide-field setup (whole-window chamber) to a total dose of 50 Gy. The tumors were optically observed daily for seven days postirradiation. Microvascular changes in the tumor and surrounding normal tissue differed greatly between the wide-field and microbeam treatments. We present evidence that these changes may be due to dissimilar spatial and temporal patterns of HIF-1 expression induced through radiation bystander effects.
Collapse
Affiliation(s)
- Andrew N Fontanella
- a Department of Biomedical Engineering, Duke University, Durham, North Carolina
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ning G, Chen R, Li Y, Wu Q, Wu Q, Li Y, Feng S. X-irradiation for inhibiting glial scar formation in injured spinal cord. Neural Regen Res 2013; 8:1582-9. [PMID: 25206454 PMCID: PMC4145965 DOI: 10.3969/j.issn.1673-5374.2013.17.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2012] [Accepted: 03/27/2013] [Indexed: 11/23/2022] Open
Abstract
X-irradiation has a beneficial effect in treating spinal cord injury. We supposed that X-irradiation could improve the microenvironment at the site of a spinal cord injury and inhibit glial scar formation. Thus, this study was designed to observe the effects of 8 Gy X-irradiation on the injury site at 6 hours and 2, 4, 7, and 14 days post injury, in terms of improvement in the microenvironment and hind limb motor function. Immunohistochemistry showed that the expression of macrophage marker ED-1 and the area with glial scar formation were reduced. In addition, the Basso, Beattie and Bresnahan score was higher at 7 days post injury relative to the other time points post injury. Results indicated that X-irradiation at a dose of 8 Gy can inhibit glial scar formation and alleviate the inflammatory reaction, thereby repairing spinal cord injury. X-irradiation at 7 days post spinal cord injury may be the best time window.
Collapse
Affiliation(s)
- Guangzhi Ning
- Department of Orthopedics, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - Renhui Chen
- Department of Orthopedics, Tianjin 4th Central Hospital, Tianjin 300140, China
| | - Yulin Li
- Department of Orthopedics, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - Qiang Wu
- Department of Orthopedics, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - Qiuli Wu
- Department of Orthopedics, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - Yan Li
- Department of Orthopedics, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - Shiqing Feng
- Department of Orthopedics, Tianjin Medical University General Hospital, Tianjin 300052, China
| |
Collapse
|